N4 Pharma Past Earnings Performance

Past criteria checks 0/6

N4 Pharma's earnings have been declining at an average annual rate of -0.6%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually. Revenues have been declining at an average rate of 51.2% per year.

Key information

-0.6%

Earnings growth rate

18.4%

EPS growth rate

Pharmaceuticals Industry Growth14.1%
Revenue growth rate-51.2%
Return on equity-87.7%
Net Margin-18,399.9%
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Companies Like N4 Pharma (LON:N4P) Are In A Position To Invest In Growth

Oct 11
Companies Like N4 Pharma (LON:N4P) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About N4 Pharma's (LON:N4P) Cash Burn Situation

Jul 06
Here's Why We're Not Too Worried About N4 Pharma's (LON:N4P) Cash Burn Situation

Should Shareholders Have Second Thoughts About A Pay Rise For N4 Pharma Plc's (LON:N4P) CEO This Year?

Mar 18
Should Shareholders Have Second Thoughts About A Pay Rise For N4 Pharma Plc's (LON:N4P) CEO This Year?

Here's What We Think About N4 Pharma's (LON:N4P) CEO Pay

Mar 01
Here's What We Think About N4 Pharma's (LON:N4P) CEO Pay

Companies Like N4 Pharma (LON:N4P) Can Afford To Invest In Growth

Dec 07
Companies Like N4 Pharma (LON:N4P) Can Afford To Invest In Growth

Revenue & Expenses Breakdown

How N4 Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

AIM:N4P Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-111
31 Mar 240-111
31 Dec 230-111
30 Sep 230-110
30 Jun 230-110
31 Mar 230-110
31 Dec 220-111
30 Sep 220-111
30 Jun 220-111
31 Mar 220-111
31 Dec 210-211
30 Sep 210-211
30 Jun 210-211
31 Mar 210-211
31 Dec 200-111
30 Sep 200-111
30 Jun 200-110
31 Mar 200-110
31 Dec 190-110
30 Sep 190-110
30 Jun 190-111
31 Mar 190-111
31 Dec 180-111
30 Sep 180-111
30 Jun 180001
31 Mar 180000
31 Dec 170-100
30 Jun 170-200
31 Mar 170-100

Quality Earnings: N4P is currently unprofitable.

Growing Profit Margin: N4P is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: N4P is unprofitable, and losses have increased over the past 5 years at a rate of 0.6% per year.

Accelerating Growth: Unable to compare N4P's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: N4P is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.2%).


Return on Equity

High ROE: N4P has a negative Return on Equity (-87.74%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies